GNSC and others will stomp dnap in personalized medicine and ORCH and others will stomp dnap in forensics. Those companies all have deals, revenues, certifications, patents and other important things that have so far eluded dnap. Maybe the dnap science is just no good? Maybe the managers cant be blamed for not being able to sell a pig in a poke? Who knows?